316
1.
Blockade Therapy. Cancer Discov 8:1069–1086
317
318
2.
3.
4.
Antonia SJ, Villegas A, Daniel D, et al (2018) Overall Survival with Durvalumab after
Chemoradiotherapy in Stage III NSCLC. N Engl J Med 379:2342–2350
323
324
Antonia SJ, Villegas A, Daniel D, et al (2017) Durvalumab after Chemoradiotherapy in Stage III
Non-Small-Cell Lung Cancer. N Engl J Med 377:1919–1929
321
322
Morad G, Helmink BA, Sharma P, et al (2021) Hallmarks of response, resistance, and toxicity to
immune checkpoint blockade. Cell 184:5309–5337
319
320
Wei SC, Duffy CR, Allison JP (2018) Fundamental Mechanisms of Immune Checkpoint
5.
Faivre-Finn C, Vicente D, Kurata T, et al (2021) Four-Year Survival With Durvalumab After
325
Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol
326
16:860–867
19
327
6.
require CD8+ T cells: changing strategies for cancer treatment. Blood 114:589–595
328
329
7.
8.
334
335
336
337
338
Chen J, Cao Y, Markelc B, et al (2019) Type I IFN protects cancer cells from CD8+ T cellmediated cytotoxicity after radiation. J Clin Invest 129:4224–4238
332
333
Gupta A, Probst HC, Vuong V, et al (2012) Radiotherapy Promotes Tumor-Specific Effector CD8
+ T Cells via Dendritic Cell Activation. J Immunol 189:558–566
330
331
Lee Y, Auh SL, Wang Y, et al (2009) Therapeutic effects of ablative radiation on local tumor
9.
Blair TC, Bambina S, Alice AF, et al (2020) Dendritic Cell Maturation Defines Immunological
Responsiveness of Tumors to Radiation Therapy. J Immunol 204:3416–3424
10. De La Maza L, Wu M, Wu L, et al (2017) In Situ Vaccination after Accelerated Hypofractionated
Radiation and Surgery in a Mesothelioma Mouse Model. Clin Cancer Res 23:5502–5513
11. Bos PD, Plitas G, Rudra D, et al (2013) Transient regulatory T cell ablation deters oncogenedriven breast cancer and enhances radiotherapy. J Exp Med 210:2435–2466
339
12. Kohno M, Murakami J, Wu L, et al (2020) Foxp3+ Regulatory T Cell Depletion after Nonablative
340
Oligofractionated Irradiation Boosts the Abscopal Effects in Murine Malignant Mesothelioma. J
341
Immunol 205:2519–2531
342
343
344
13. Wei J, Montalvo-Ortiz W, Yu L, et al (2021) Sequence of αPD-1 relative to local tumor irradiation
determines the induction of abscopal antitumor immune responses. Sci Immunol 6:eabg0117
14. Liang H, Deng L, Hou Y, et al (2017) Host STING-dependent MDSC mobilization drives
20
345
346
347
348
349
350
351
extrinsic radiation resistance. Nat Commun 8:1736
15. Jones KI, Tiersma J, Yuzhalin AE, et al (2018) Radiation combined with macrophage depletion
promotes adaptive immunity and potentiates checkpoint blockade. EMBO Mol Med 10:e9342
16. Baumann T, Dunkel A, Schmid C, et al (2020) Regulatory myeloid cells paralyze T cells through
cell-cell transfer of the metabolite methylglyoxal. Nat Immunol 21:555–566
17. Bergonié J, Tribondeau L (2003) Interpretation of some results from radiotherapy and an attempt
to determine a rational treatment technique. 1906. Yale J Biol Med 76:181–182
352
18. Dunn PL, North RJ (1991) Selective radiation resistance of immunologically induced T cells as
353
the basis for irradiation-induced T-cell-mediated regression of immunogenic tumor. J Leukoc
354
Biol 49:388–396
355
19. Alexandru M, Rodica A, Dragos-Eugen G, et al (2021) Assessing the Spleen as an Organ at Risk
356
in Radiation Therapy and Its Relationship With Radiation-Induced Lymphopenia: A
357
Retrospective Study and Literature Review. Adv Radiat Oncol 6:100761
358
359
360
361
362
20. Schrek R, Stefani S (1964) Radioresistance of Phytohemagglutinin-Treat- ed Normal and
Leukemic Lymphocytes I, 2. Journal of the National Cancer Institute 32:507–521
21. Carloni M, Meschini R, Ovidi L, Palitti F (2001) PHA-induced cell proliferation rescues human
peripheral blood lymphocytes from X-ray-induced apoptosis. Mutagenesis 16:115–120
22. Heylmann D, Badura J, Becker H, et al (2018) Sensitivity of CD3/CD28-stimulated versus non-
21
363
stimulated lymphocytes to ionizing radiation and genotoxic anticancer drugs: key role of ATM in
364
the differential radiation response. Cell Death Dis 9:1053
365
366
367
368
369
370
371
372
373
374
375
376
377
378
23. Grayson JM, Harrington LE, Lanier JG, et al (2002) Differential sensitivity of naive and memory
CD8+ T cells to apoptosis in vivo. J Immunol 169:3760–3770
24. Arina A, Beckett M, Fernandez C, et al (2019) Tumor-reprogrammed resident T cells resist
radiation to control tumors. Nat Commun 10:3959
25. Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity
39:1–10
26. Galluzzi L, Vitale I, Warren S, et al (2020) Consensus guidelines for the definition, detection and
interpretation of immunogenic cell death. J Immunother Cancer 8:e000337
27. Galluzzi L, Buqué A, Kepp O, et al (2017) Immunogenic cell death in cancer and infectious
disease. Nat Rev Immunol 17:97–111
28. Hernandez C, Huebener P, Schwabe RF (2016) Damage-associated molecular patterns in cancer:
a double-edged sword. Oncogene 35:5931–5941
29. Golden EB, Frances D, Pellicciotta I, et al (2014) Radiation fosters dose-dependent and
chemotherapy-induced immunogenic cell death. Oncoimmunology 3:e28518
379
30. Gardner A, Ruffell B (2016) Dendritic Cells and Cancer Immunity. Trends Immunol 37:855–865
380
31. Ablasser A, Schmid-Burgk JL, Hemmerling I, et al (2013) Cell intrinsic immunity spreads to
22
381
382
383
bystander cells via the intercellular transfer of cGAMP. Nature 503:530–534
32. Fuertes MB, Kacha AK, Kline J, et al (2011) Host type I IFN signals are required for antitumor
CD8+ T cell responses through CD8 alpha+ dendritic cells. J Exp Med 208:2005–2016
384
33. Deng L, Liang H, Xu M, et al (2014) STING-Dependent Cytosolic DNA Sensing Promotes
385
Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
386
Immunity 41:843–852
387
388
389
390
391
392
393
394
395
396
397
398
34. Vanpouille-Box C, Alard A, Aryankalayil MJ, et al (2017) DNA exonuclease Trex1 regulates
radiotherapy-induced tumour immunogenicity. Nat Commun 8:15618
35. Mackenzie KJ, Carroll P, Martin C-A, et al (2017) cGAS surveillance of micronuclei links
genome instability to innate immunity. Nature 548:461–465
36. Flynn PJ, Koch PD, Mitchison TJ (2021) Chromatin bridges, not micronuclei, activate cGAS
after drug-induced mitotic errors in human cells. Proc Natl Acad Sci U S A 118:e2103585118
37. Schröder-Heurich B, Wieland B, Lavin MF, et al (2014) Protective role of RAD50 on chromatin
bridges during abnormal cytokinesis. FASEB J 28:1331–1341
38. Zhao Y, Zhang T, Wang Y, et al (2021) ICAM-1 orchestrates the abscopal effect of tumor
radiotherapy. Proc Natl Acad Sci U S A 118:e2010333118
39. Harlin H, Meng Y, Peterson AC, et al (2009) Chemokine expression in melanoma metastases
associated with CD8+ T-cell recruitment. Cancer Res 69:3077–3085
23
399
400
40. Matsumura S, Wang B, Kawashima N, et al (2008) Radiation-induced CXCL16 release by breast
cancer cells attracts effector T cells. J Immunol 181:3099–3107
401
41. Lugade AA, Sorensen EW, Gerber SA, et al (2008) Radiation-induced IFN-gamma production
402
within the tumor microenvironment influences antitumor immunity. J Immunol 180:3132–3139
403
42. Matsumura S, Demaria S (2010) Up-regulation of the pro-inflammatory chemokine CXCL16 is
404
a common response of tumor cells to ionizing radiation. Radiat Res 173:418–425
405
43. Lugade AA, Moran JP, Gerber SA, et al (2005) Local Radiation Therapy of B16 Melanoma
406
Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the
407
Tumor. J Immunol 174:7516–7523
408
44. Rodriguez-Ruiz ME, Garasa S, Rodriguez I, et al (2017) Intercellular Adhesion Molecule-1 and
409
Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium.
410
Int J Radiat Oncol Biol Phys 97:389–400
411
412
45. Slaney CY, Kershaw MH, Darcy PK (2014) Trafficking of T cells into tumors. Cancer Res
74:7168–7174
413
46. Yanguas A, Garasa S, Teijeira Á, et al (2018) ICAM-1-LFA-1 Dependent CD8+ T-Lymphocyte
414
Aggregation in Tumor Tissue Prevents Recirculation to Draining Lymph Nodes. Front Immunol
415
9:2084
416
47. Riaz N, Havel JJ, Makarov V, et al (2017) Tumor and Microenvironment Evolution during
24
417
Immunotherapy with Nivolumab. Cell 171:934-949
418
48. Benci JL, Johnson LR, Choa R, et al (2019) Opposing Functions of Interferon Coordinate
419
Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell 178:933-
420
948
421
49. Reits EA, Hodge JW, Herberts CA, et al (2006) Radiation modulates the peptide repertoire,
422
enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med
423
203:1259–1271
424
50. Sharabi AB, Nirschl CJ, Kochel CM, et al (2015) Stereotactic Radiation Therapy Augments
425
Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of
426
Tumor Antigen. Cancer Immunol Res 3:345–355
427
51. Zebertavage LK, Alice A, Crittenden MR, et al (2020) Transcriptional Upregulation of NLRC5
428
by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and
429
T Cell Cytotoxicity. Sci Rep 10:7376
430
431
52. Lhuillier C, Rudqvist N-P, Yamazaki T, et al (2021) Radiotherapy-exposed CD8+ and CD4+
neoantigens enhance tumor control. J Clin Invest 131:e138740
432
53. Lussier DM, Alspach E, Ward JP, et al (2021) Radiation-induced neoantigens broaden the
433
immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A
434
118:e2102611118
25
435
436
437
438
54. van der Merwe PA, Bodian DL, Daenke S, et al (1997) CD80 (B7-1) binds both CD28 and CTLA4 with a low affinity and very fast kinetics. J Exp Med 185:393–403
55. Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 Pathways: Similarities, Differences, and
Implications of Their Inhibition. Am J Clin Oncol 39:98–106
439
56. Freeman GJ, Long AJ, Iwai Y, et al (2000) Engagement of the PD-1 immunoinhibitory receptor
440
by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med
441
192:1027–1034
442
443
444
445
57. Latchman Y, Wood CR, Chernova T, et al (2001) PD-L2 is a second ligand for PD-1 and inhibits
T cell activation. Nat Immunol 2:261–268
58. Keir ME, Liang SC, Guleria I, et al (2006) Tissue expression of PD-L1 mediates peripheral T
cell tolerance. J Exp Med 203:883–895
446
59. Iwai Y, Ishida M, Tanaka Y, et al (2002) Involvement of PD-L1 on tumor cells in the escape from
447
host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A
448
99:12293–12297
449
450
451
452
60. Scheper W, Kelderman S, Fanchi LF, et al (2019) Low and variable tumor reactivity of the
intratumoral TCR repertoire in human cancers. Nat Med 25:89–94
61. Valpione S, Mundra PA, Galvani E, et al (2021) The T cell receptor repertoire of tumor infiltrating
T cells is predictive and prognostic for cancer survival. Nat Commun 12:4098
26
453
454
455
456
457
458
459
460
461
462
463
464
62. Twyman-Saint Victor C, Rech AJ, Maity A, et al (2015) Radiation and dual checkpoint blockade
activate non-redundant immune mechanisms in cancer. Nature 520:373–377
63. Rudqvist N-P, Pilones KA, Lhuillier C, et al (2018) Radiotherapy and CTLA-4 Blockade Shape
the TCR Repertoire of Tumor-Infiltrating T Cells. Cancer Immunol Res 6:139–150
64. Im SJ, Hashimoto M, Gerner MY, et al (2016) Defining CD8+ T cells that provide the
proliferative burst after PD-1 therapy. Nature 537:417–421
65. Sato H, Okonogi N, Nakano T (2020) Rationale of combination of anti-PD-1/PD-L1 antibody
therapy and radiotherapy for cancer treatment. Int J Clin Oncol 25:801–809
66. Sato H, Niimi A, Yasuhara T, et al (2017) DNA double-strand break repair pathway regulates PDL1 expression in cancer cells. Nat Commun 8:1751
67. Kachikwu EL, Iwamoto KS, Liao Y-P, et al (2011) Radiation Enhances Regulatory T Cell
Representation. Int J Radiat Oncol Biol Phys 81:1128–1135
465
68. Muroyama Y, Nirschl TR, Kochel CM, et al (2017) Stereotactic Radiotherapy Increases
466
Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment. Cancer Immunol
467
Res 5:992–1004
468
469
470
69. Zappasodi R, Serganova I, Cohen IJ, et al (2021) CTLA-4 blockade drives loss of Treg stability
in glycolysis-low tumours. Nature 591:652–658
70. Demaria S, Kawashima N, Yang AM, et al (2005) Immune-mediated inhibition of metastases
27
471
after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.
472
Clin Cancer Res 11:728–734
473
474
71. Formenti SC, Rudqvist N-P, Golden E, et al (2018) Radiotherapy induces responses of lung
cancer to CTLA-4 blockade. Nat Med 24:1845–1851
475
72. Sia J, Hagekyriakou J, Chindris I, et al (2021) Regulatory T Cells Shape the Differential Impact
476
of Radiation Dose-Fractionation Schedules on Host Innate and Adaptive Antitumor Immune
477
Defenses. Int J Radiat Oncol Biol Phys 111:502–514
478
479
73. Gunderson AJ, Young KH (2018) Exploring optimal sequencing of radiation and immunotherapy
combinations. Adv Radiat Oncol 3:494–505
480
74. Siddiqui I, Schaeuble K, Chennupati V, et al (2019) Intratumoral Tcf1+PD-1+CD8+ T Cells with
481
Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint
482
Blockade Immunotherapy. Immunity 50:195–211
483
75. Pomeranz Krummel DA, Nasti TH, Izar B, et al (2020) Impact of Sequencing Radiation Therapy
484
and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases. Int J Radiat
485
Oncol Biol Phys 108:157–163
486
487
488
76. Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin
Invest 117:1147–1154
77. Metz R, Rust S, Duhadaway JB, et al (2012) IDO inhibits a tryptophan sufficiency signal that
28
489
stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.
490
Oncoimmunology 1:1460–1468
491
492
493
494
78. Chen B, Alvarado DM, Iticovici M, et al (2020) Interferon-Induced IDO1 Mediates Radiation
Resistance and Is a Therapeutic Target in Colorectal Cancer. Cancer Immunol Res 8:451–464
79. Thomas SR, Stocker R (1999) Redox reactions related to indoleamine 2,3-dioxygenase and
tryptophan metabolism along the kynurenine pathway. Redox Rep 4:199–220
495
80. Ju J-M, Nam G, Lee Y-K, et al (2021) IDO1 scavenges reactive oxygen species in myeloid-
496
derived suppressor cells to prevent graft-versus-host disease. Proc Natl Acad Sci U S A
497
118:e2011170118
498
81. Watanabe T, Gaedicke S, Guffart E, et al (2020) Adding Indoximod to Hypofractionated
499
Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8+ T-Cell–
500
Dependent Tumor ActivityEffects of Indoximod on Radiotherapy plus Anti-PD-1. Clin Cancer
501
Res 26:945–956
502
82. Van den Eynde BJ, van Baren N, Baurain J-F (2020) Is There a Clinical Future for IDO1
503
Inhibitors After the Failure of Epacadostat in Melanoma? Annu Rev Cancer Biol 4:241–256
29
Radiotherapy (RT)
Tumor microenvironment
CD8+T-cell
proliferation
[step 6, 7] RT enhances tumor immunogenicity
and helps antigen-specific T-cells
recognize and kill tumor cells.
RT-induced
peptide- MHC I complex
antigen-specific T-cells
Tumor antigen
MHC I
tumor
cell kill
[step 4, 5] RT enhances
T-cell trafficking & infiltration
Endothelium
[step 3] RT enhances priming of
antigen-specific T cells
ICAM-1
Integrin
MHC I TCR
[step 1] RT-induced
immunogenic cell death
[step 2] RT-induced
DC maturation and
antigen release from tumors
cGAS-STING
pathway
CD80 CD28
/86
Tumor-antigen, DAMPs, IFNs
Tumor-draining lymph nodes
Tumor cell
Dead
tumor cell
Dendritic
cell
CD8+T-cell
Irradiated site
Immune
suppressor cell
Activated cells
...
論文の公開元へ
